Transporting irreplaceable products means having trust in the technology Cell and gene therapies could be flying high soon, joining the medical supplies, whole blood products, and even organs being transported by drones. In collaboration with RPS Aerospace, the Italy-based biotech company Anemocyte developed a remotely piloted drone system to securely transport final cell and gene
Novel automation technologies enable the decentralized manufacturing of highly standardized CAR-T cell products in academic GMP facilities experienced with the production of patient-individual cell therapies. Dr Janet Rossig discusses the benefits of academic cell manufacturing, namely supporting the informed dissemination of CAR-T cell therapy to patients who benefit from this modality. She argues that this
Source NIH Researchers continue to make progress with cancer immunotherapy, a type of treatment that harnesses the body’s own immune cells to attack cancer. But Kole Roybal wants to help move the field further ahead by engineering patients’ immune cells to detect an even broader range of cancers and then launch customized attacks against them.
Source PMLive Dr Stuart Adams specialises in using T-cell therapy to treat paediatric patients at Great Ormond Street Hospital. Here, he explains what it was like to develop and deliver a groundbreaking CAR-T therapy for the first patient in Europe, and how the centre of excellence has adapted to make precision medicine a reality Dr
Many of the efforts to improve on the first generation of CAR-T therapies such that they can reach solid tumors had focused on tweaks inherent to the cancer killing agent — specifically, utilizing more potent T cells as their base, from stem memory T cells to virally associated T cells to marrow infiltrating lymphocytes. But
Article Highlights CAR T-cell therapy is gaining traction in relapsed/refractory lymphoma in older patients with aggressive disease. As a result of prospective trials investigating CAR T-cell therapy, there is potential that older patients with lymphoma can be spared multiple lines of chemotherapy and its resultant toxicities while still having long-term clinical benefit. Toxicities are still
A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumour attack. Since then CAR T approaches (one of several strategies collectively known as “adoptive T cell transfer”) have made headlines
Source Nature From antibiotics and organoids to CRISPR, improved biomedical methods and apparatus are enabling new therapies. Organoids Mini organs stand in for test models The term ‘organoid’ didn’t exist a decade ago. Now it’s a buzzword in biomedical science for a three-dimensional multi-cellular structure or ‘mini organ’. Thanks to advances with pluripotent stem cells
In this interview with Bruce Levine Ph.D. (University of Pennsylvania, PA, USA) we find out about his talk on constantly enhancing and improving engineered T cells, which was presented recently at the American Association for Cancer Research (AACR) Annual Meeting (March 29–April 3, 2019, Atlanta, GA, USA). In addition, we also asked about his thoughts
An advance in the groundbreaking cancer treatment known as CAR T-cell therapy appears to eliminate its severe side effects, making the treatment safer and potentially available in outpatient settings, a new USC study shows. “This is a major improvement,” said Si-Yi Chen of the USC Norris Comprehensive Cancer Center, professor in the Department of Molecular Microbiology
